Authors
Shiva Velayati, Masoumeh Zahmatkeshan, Fariba Esmaeili, Seyed Mohammad Hosseini, Seyed Mahdi Rezayat, Mahmoud Reza Jaafari, Kazem Mousavizadeh, Gholamreza Taheripak, Moein Adel, Anna Lesniak, Iraj Alipourfard
Published in
Journal of nanobiotechnology. Volume 24. Issue 1. Jul 27, 2026. Epub Jul 27, 2026.
Abstract
Metal-organic frameworks (MOFs) have garnered significant attention as versatile nanocarriers for oncological drug delivery, owing to their exceptional porosity, structural tunability, extensive specific surface areas, and favorable drug loading and release kinetics, which collectively enable targeted payload delivery and reduced systemic toxicity. Nevertheless, the clinical promise of unmodified MOFs is severely curtailed by substantial in vivo biological barriers-including rapid bio-clearance, the immunosuppressive and acidic tumor microenvironment (TME), and inefficient cellular internalization-challenges that are ubiquitous across nanomedicine platforms and critically undermine therapeutic outcomes. This review provides a comprehensive examination of post-synthetic modification (PSM) as an indispensable strategy to surmount these obstacles. It systematically categorizes the diverse array of surface modifiers reported to date into natural polymers, synthetic polymers, nonpolymeric small molecules, inorganic materials, and multifunctional hybrid architectures, while elucidating how each class can enhance biocompatibility, colloidal stability, circulation half-life, active targeting, and stimuli-responsive cargo release. Crucially, the review critically appraises the intrinsic trade-offs introduced by surface engineering, including increased hydrodynamic diameter, impaired tumor penetration, heightened synthetic and characterization complexity, and unpredictable perturbations to biodegradation pathways and immune system interactions. Despite robust preclinical validation, the translational trajectory of surface-engineered MOF-based therapeutics remains encumbered by formidable challenges spanning scalable and reproducible manufacturing, long-term biosafety assessment, and stringent regulatory approval. By delineating current advances, critical limitations, and prospective directions, this review highlights the delicate equilibrium between surface functionalization and biological performance that must be achieved to realize the clinical potential of PSM-optimized MOF nanomedicines.
PMID:
42907997
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 18
- Comments 0